Abstract 5205: B6- KrasLSL-G12C mouse model for assessing the occurrence and development of lung and pancreatic cancer tumors

• Published in: Cancer research (Chicago, Ill.) Vol. 83; no. 7_Supplement; p. 5205
• Main Authors: Yang, Xiaoliu, Jiang, Yunlong, Wu, Xue, Zhang, Mingkun, Zhao, Jing, Chen, Santi Suryani, Li, Zhiying, Trujillo, Erica, Moore, Mark Wade, Gao, Xiang, Ju, Cunxiang
• Format: Journal Article
• Language: English
• Published: 04.04.2023
• ISSN: 1538-7445; 1538-7445
• DOI: 10.1158/1538-7445.AM2023-5205

Abstract In May 2021, the FDA approved sotorasib (Lumakras™) as the first treatment for adult patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C genetic mutation. To study the relationship between the mutational activation of KRAS and tumorigenesis, and promote the development of KRAS-G12C inhibitors, we established the B6-Loxp-Stop-Loxp Kras G12C (B6-KrasLSL-G12C) strain. Upon induction of Cre recombinase, floxed Stop sequences will be deleted in the mouse genome, and the oncogenic KRAS-G12C protein will be expressed at endogenous levels allowing for control of the timing and location of tumor initiation. The C57BL/6-KrasLSL-G12C mice were crossed with the Lyz2-cre mice to develop a spontaneous lung cancer model. KRAS G12C mutant could be detected in type II alveolar epithelial cells (ATII). Furthermore, these mice develop lung cancer at 8-10 weeks of age. In addition, when B6-KrasLSL-G12C mice were crossed with the B6-P53LSL-R172H and Ptf1/p48-Cre mice, the offspring developed pancreatic cancer after 10-12 weeks of tamoxifen treatment. In conclusion, B6-KrasLSL-G12C mice can be used to study the occurrence and development of pancreatic and lung cancer, as well as the potential applications of cancer therapies. Citation Format: Xiaoliu Yang, Yunlong Jiang, Xue Wu, Mingkun Zhang, Jing Zhao, Santi Suryani Chen, Zhiying Li, Erica Trujillo, Mark Wade Moore, Xiang Gao, Cunxiang Ju. B6-KrasLSL-G12C mouse model for assessing the occurrence and development of lung and pancreatic cancer tumors. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5205.